Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.75 |
| ▸ | NPC1 | O15118 | 6/20 | 0.75 |
| ▸ | RAB9A | P51151 | 5/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | GLA | P06280 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | CCR1 | P32246 | 2/20 | 0.54 |
| ▸ | CCR5 | P51681 | 2/20 | 0.54 |
| ▸ | CCR8 | P51685 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | METAP1 | P53582 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.54 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3827117 | 0.98 | KDM4E (0.72) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL14307217 | 0.96 | KDM4E (0.76) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL3069800 | 0.86 | KDM4E (1.00) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL28857293 | 0.84 | KDM4E (0.95) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL12803325 | 0.79 | KDM4E (0.69) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL12529393 | 0.78 | KDM4E (0.67) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL20809152 | 0.78 | KDM4E (0.61) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL11996764 | 0.77 | HDAC1 (0.48) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL20382465 | 0.77 | KDM4E (0.72) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL10960575 | 0.77 | KDM4E (0.72) | KDM4ENPC1RAB9AMAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| EP-3885343-A1 | INDOLE COMPOUNDS AS EZH2 INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210230150-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | AMIRA THERAPEUTICS, S.L. (ES) | 2021-07-29 | — | — | US | disclosed |
| WO-2020247575-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3725775-A1 | PYRIDINE- AND PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | Syntrix Biosystems, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3722284-A1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2020-10-14 | — | — | EP | disclosed |
| US-6613747-B2 | Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-02 | — | — | US | disclosed |
| WO-2003048081-A2 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003047520-A2 | SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003026652-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| US-6472372-B1 | 6-O-Carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2002046204-A1 | 6-0-CARBAMOYL KETOLIDE DERIVATIVES OF ERYTHROMYCIN USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20020063516-A1 | Limuninescence device, display apparatus and metal coordination compound | CANON KABUSHIKI KAISHA (JP) | 2002-05-30 | — | — | US | disclosed |
| EP-1191612-A2 | Luminescence device, display apparatus and metal coordination compound | CANON KABUSHIKI KAISHA (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2437/4885NPC1 868/4885RAB9A 936/4885 |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | KDM4E 2919/4885NPC1 2990/4885RAB9A 3308/4885 |
| US-20210230150-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | UGT1A3, UGT1A1, UGT1A6 | KDM4E 1983/4885NPC1 126/4885RAB9A 3191/4885 |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | Q6ZSR9, HK1, KDM4E | KDM4E 3/4885NPC1 3251/4885RAB9A 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.